[1]张浩,赵婧,葛小宁,等.甲状腺相关性眼病的诊断性生物标志物研究进展[J].眼科新进展,2022,42(7):562-567.[doi:10.13389/j.cnki.rao.2022.0115]
　ZHANG Hao,ZHAO Jing,GE Xiaoning,et al.Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(7):562-567.[doi:10.13389/j.cnki.rao.2022.0115]
点击复制

甲状腺相关性眼病的诊断性生物标志物研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年7期
页码:
562-567
栏目:
文献综述
出版日期:
2022-07-05

文章信息/Info

Title:
Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy
作者:
张浩; 赵婧; 葛小宁; 董雅儒
130041　吉林省长春市 吉林大学第二医院眼科
Author(s):
ZHANG Hao; ZHAO Jing; GE Xiaoning; DONG Yaru
Department of Ophthalmology，the Second Hospital of Jilin University，Changchun 130041，Jilin Province，China
关键词:
甲状腺相关性眼病; 生物标志物; 血液; 尿液; 泪液
Keywords:
thyroid-associated ophthalmopathy;  biomarker;  blood;  urine;  tear
分类号:
R771.3
DOI:
10.13389/j.cnki.rao.2022.0115
文献标志码:
A
摘要:
甲状腺相关性眼病（TAO）是由自身免疫反应引起的慢性致盲性眼部疾病，其与甲状腺功能障碍密切相关。TAO的诊断主要基于眼部临床表现、体征、实验室检查、影像学特征以及甲状腺功能障碍病史。迄今为止，该病尚无特异性标志物，这给TAO的早期诊断带来巨大困难，尤其部分TAO患者在诊断为甲状腺功能障碍前就表现出难以忍受的眼部症状。因此，实现TAO早期诊断并给予相应干预，控制其进一步恶化，将对患者的预后及生活质量有着重要意义。本文将简要讨论TAO的致病因素、发病机制以及诊断局限性，重点对近年来TAO诊断性生物标志物研究进展予以综述。
Abstract:
Thyroid-associated ophthalmopathy (TAO) is a chronic blinding disease caused by autoimmune reactions, which is closely related to thyroid dysfunction. The diagnosis of TAO is mainly based on ocular manifestations, signs, laboratory tests, imaging features, as well as a history of thyroid dysfunction. To date, there is no specific marker for this disease, which poses great difficulties in the early diagnosis of TAO, especially for a few TAO patients who have shown unbearable eye symptoms before the diagnosis of thyroid dysfunction. Therefore, early diagnosis of TAO and corresponding intervention are of great significance to prevent its deterioration and improve the prognosis and quality of life of patients. This article briefly discusses the pathogenic factors, pathogenesis, and diagnostic limitations of TAO, with focus on the recent research progress in diagnostic biomarkers for TAO.

参考文献/References:

［1］　SMITH T J,HEGEDS L.Graves’ disease［J］.N Engl J Med,2016,375(16):1552-1565.
［2］　MOSTAFAVI D,POINTDUJOUR R,GUTMAN J,SHINDER R.Isolated lateral rectus muscle involvement as a presenting sign of euthyroid Graves disease［J］.J AAPOS,2012,16(2):216-217.
［3］　PANAGIOTOU G,PERROS P.Asymmetric Graves’ orbitopathy［J］.Front Endocrinol (Lausanne),2020,11:611845.
［4］　MARIN M,IONNI I,LANZOLLA G,SFRAMELI A,LATROFA F,ROCCHI R,et al.Orbital diseases mimicking Graves’ orbitopathy:a long-standing challenge in differential diagnosis［J］.J Endocrinol Invest,2020,43(4):401-411.
［5］　MENCONI F,PROFILO M A,LEO M,SISTI E,ALTEA M A,ROCCHI R,et al.Spontaneous improvement of untreated mild Graves’ ophthalmopathy:Rundle’s curve revisited［J］.Thyroid,2014,24(1):60-66.
［6］　BARTALENA L,PIANTANIDA E,GALLO D,LAI A,TANDA M L.Epidemiology,natural history,risk factors,and prevention of Graves’ orbitopathy［J］.Front Endocrinol (Lausanne),2020,11:615993.
［7］　TOMER Y.Mechanisms of autoimmune thyroid diseases:from genetics to epigenetics［J］.Annu Rev Pathol,2014,9:147-156.
［8］　NMETH K,DARVASI O,LIK I,SZCS N,CZIRJK S,REINIGER L,et al.Next-generation sequencing identifies novel mitochondrial variants in pituitary adenomas［J］.J Endocrinol Invest,2019,42(8):931-940.
［9］　BARTALENA L.Prevention of Graves’ ophthalmopathy［J］.Best Pract Res Clin Endocrinol Metab,2012,26(3):371-379.
［10］　KRIEGER C C,PLACE R F,BEVILACQUA C,MARCUS-SAMUELS B,ABEL B S,SKARULIS M C,et al.TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis［J］.J Clin Endocrinol Metab,2016,101(6):2340-2347.
［11］　KRIEGER C C,BOUTIN A,JANG D,MORGAN S J,BANGA J P,GJ K,et al.Arrestin-β-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk［J］.Endocrinology,2019,160(6):1468-1479.
［12］　SMITH T J,JANSSEN J.Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy［J］.Endocr Rev,2019,40(1):236-267.
［13］　BARRIO-BARRIO J,SABATER A L,BONET-FARRIOL E,VELZQUEZ-VILLORIA ,GALOFR J C.Graves’ ophthalmopathy:VISA versus EUGOGO classification,assessment,and management［J］.J Ophthalmol,2015,2015:249125.
［14］　FOX T J,ANASTASOPOULOU C,DOLMAN P J.Evaluating Graves’ orbitopathy［J］.Best Pract Res Clin Endocrinol Metab,2012,26(3):229-248.
［15］　WOO Y J,JANG S Y,LIM T H,YOON J S.Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves’ orbitopathy［J］.Korean J Ophthalmol,2015,29(4):213-219.
［16］　SEO S,SNCHEZ R M.Usefulness of TSH receptor antibodies as biomarkers for Graves’ ophthalmopathy:a systematic review［J］.J Endocrinol Invest,2018,41(12):1457-1468.
［17］　SIAKALLIS L C,UDDIN J M,MISZKIEL K A.Imaging investigation of thyroid eye disease［J］.Ophthalmic Plast Reconstr Surg,2018,34(4 Suppl 1):S41-S51.
［18］　STRIMBU K,TAVEL J A.What are biomarkers?［J］.Curr Opin HIV AIDS,2010,5(6):463-466.
［19］　JANG S Y,SHIN D Y,LEE E J,CHOI Y J,LEE S Y,YOON J S.Correlation between TSH receptor antibody assays and clinical manifestations of Graves’ orbitopathy［J］.Yonsei Med J,2013,54(4):1033-1039.
［20］　KAMPMANN E,DIANA T,KANITZ M,HOPPE D,GJ K.Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy:a prospective study［J］.Int J Endocrinol,2015,2015:678194.
［21］　PONTO K A,KANITZ M,OLIVO P D,PITZ S,PFEIFFER N,GJ K.Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy［J］.Ophthalmology,2011,118(11):2279-2285.
［22］　DIANA T,BROWN R S,BOSSOWSKI A,SEGNI M,NIEDZIELA M,KONIG J,et al.Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves’ disease:a multicenter study［J］.J Clin Endocrinol Metab,2014,99(5):1648-1655.
［23］　PONTO K A,DIANA T,BINDER H,MATHEIS N,PITZ S,PFEIFFER N,et al.Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy［J］.J Endocrinol Invest,2015,38(7):769-777.
［24］　DIANA T,PONTO K A,GJ K.Thyrotropin receptor antibodies and Graves’ orbitopathy［J］.J Endocrinol Invest,2021,44(4):703-712.
［25］　VENTURA M,MELO M,CARRILHO F.Selenium and thyroid disease:from pathophysiology to treatment［J］.Int J Endocrinol,2017,2017:1297658.
［26］　KHONG J J,GOLDSTEIN R F,SANDERS K M,SCHNEIDER H,POPE J,BURDON K P,et al.Serum selenium status in Graves’ disease with and without orbitopathy:a case-control study［J］.Clin Endocrinol (Oxf),2014,80(6):905-910.
［27］　GONTARZ-NOWAK K,SZYCHLINSKA M,MATUSZEWSKI W,STEFANOWICZ-RUTKOWSKA M G,BANDURSKA-STANKIEWICZ E.Current knowledge on Graves’ orbitopathy［J］.J Clin Med,2020,10(1):16.
［28］　LUMYONGSATIEN M,BHAKTIKAMALA U,THONGTONG P,SINTUWONG S,NIMITWONGSAKUL O,KANOKKANTAPONG J,et al.Relative selenium insufficiency is a risk factor for developing severe Graves’ orbitopathy:a case-control study［J］.BMJ Open Ophthalmol,2021,6(1):e000713.
［29］　WINTHER K H,BONNEMA S J,HEGEDS L.Is selenium supplementation in autoimmune thyroid diseases justified?［J］.Curr Opin Endocrinol Diabetes Obes,2017,24(5):348-355.
［30］　WANG Y,ZHAO F,RIJNTJES E,WU L,WU Q,SUI J,et al.Role of selenium intake for risk and development of hyperthyroidism［J］.J Clin Endocrinol Metab,2019,104(2):568-580.
［31］　HE M,WANG Y,WANG J,SUI J,DING X,CHEN Z,et al.The potential markers involved in newly diagnosed Graves’ disease and the development of active Graves’ orbitopathy［J］.Cytokine,2020,127:154998.
［32］　DAVIES T F,ANDERSEN S,LATIF R,NAGAYAMA Y,BARBESINO G,BRITO M,et al.Graves’ disease［J］.Nat Rev Dis Primers,2020,6(1):52.
［33］　FALKOWSKI B,SZCZEPANEK-PARULSKA E,SAWICKA-GUTAJ N,KRYGIER A,RUCHALA M.Evaluation of IL-29 in euthyroid patients with Graves’ orbitopathy:a preliminary study［J］.Mediators Inflamm,2020,2020:4748612.
［34］　HUANG D,LUO Q,YANG H,MAO Y.Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy［J］.Invest Ophthalmol Vis Sci,2014,55(8):4935-4943.
［35］　NOWAK M,SIEMINSKA L,KARPE J,MAREK B,KOS-KUDLA B,KAJDANIUK D.Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy［J］.J Endocrinol Invest,2016,39(1):63-72.
［36］　SONG R H,QIN Q,WANG X,YAN N,MENG S,SHI X H,et al.Differential cytokine expression detected by protein microarray screening in peripheral blood of patients with refractory Graves’ disease［J］.Clin Endocrinol (Oxf),2016,84(3):402-407.
［37］　LI X,QI Y,MA X,HUANG F,GUO H,JIANG X,et al.Chemokine (C-C motif) ligand 20,a potential biomarker for Graves’ disease,is regulated by osteopontin［J］.PLoS One,2013,8(5):e64277.
［38］　LIGHAAM L C,RISPENS T.The immunobiology of immunoglobulin G4［J］.Semin Liver Dis,2016,36(3):200-215.
［39］　YU S H,KANG J G,KIM C S,IHM S H,CHOI M G,YOO H J,et al.Clinical implications of immunoglobulin G4 to Graves’ ophthalmopathy［J］.Thyroid,2017,27(9):1185-1193.
［40］　LUO B,YUAN X,WANG W,ZHANG J,LIU R,HU W,et al.Ocular manifestations and clinical implications of serum immunoglobulin G4 levels in Graves’ ophthalmopathy patients［J］.Ocul Immunol Inflamm,2020,2020:1-8.
［41］　BOZKIRLI E,BAKINER O S,BOZKIRLI E D,HAYDARDEDEOGLU F E,SIZMAZ S,TORUN A I,et al.Serum immunoglobulin G4 levels are elevated in patients with Graves’ ophthalmopathy［J］.Clin Endocrinol (Oxf),2015,83(6):962-967.
［42］　KIM S E,YOON J S,KIM K H,LEE S Y.Increased serum interleukin-17 in Graves’ ophthalmopathy［J］.Graefes Arch Clin Exp Ophthalmol,2012,250(10):1521-1526.
［43］　LOBEL M,BAUER S,MEISEL C,EISENREICH A,KUDERNATSCH R,TANK J,et al.CCN1:a novel inflammation-regulated biphasic immune cell migration modulator［J］.Cell Mol Life Sci,2012,69(18):3101-3113.
［44］　KULAR L,PAKRADOUNI J,KITABGI P,LAURENT M,MARTINERIE C.The CCN family:a new class of inflammation modulators?［J］.Biochimie,2011,93(3):377-388.
［45］　WOO Y J,SEO Y,KIM J J,KIM J W,PARK Y,YOON J S.Serum CYR61 is associated with disease activity in Graves’ orbitopathy［J］.Ocul Immunol Inflamm,2018,26(7):1094-1100.
［46］　LANTZ M,VONDRICHOVA T,PARIKH H,FRENANDER C,RIDDERSTRLE M,ASMAN P,et al.Overexpression of immediate early genes in active Graves’ ophthalmopathy［J］.J Clin Endocrinol Metab,2005,90(8):4784-4791.
［47］　MARCHITTI S A,BROCKER C,STAGOS D,VASILIOU V.Non-P450 aldehyde oxidizing enzymes:the aldehyde dehydrogenase superfamily［J］.Expert Opin Drug Metab Toxicol,2008,4(6):697-720.
［48］　LANZOLLA G,MARCOCCI C,MARIN M.Oxidative stress in graves disease and Graves’ orbitopathy［J］.Eur Thyroid J,2020,9(Suppl 1):40-50.
［49］　CHENG K C,WU Y J,CHENG K H,CHENG K Y,CHEN K J,WU W C,et al.Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves’ orbitopathy［J］.Graefes Arch Clin Exp Ophthalmol,2018,256(6):1195-1201.
［50］　BYEON S K,PARK S H,LEE J C,HWANG S,KU C R,SHIN D Y,et al.Lipidomic differentiation of Graves’ ophthalmopathy in plasma and urine from Graves’ disease patients［J］.Anal Bioanal Chem,2018,410(27):7121-7133.
［51］　WANG Y,SMITH T J.Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy［J］.Invest Ophthalmol Vis Sci,2014,55(3):1735-1748.
［52］　MARTINS J R,FURLANETTO R P,OLIVEIRA L M,MENDES A,PASSEROTTI C C,CHIAMOLERA M I,et al.Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves’ ophthalmopathy［J］.Clin Endocrinol (Oxf),2004,60(6):726-733.
［53］　HENRY L G,MCKENZIE R M,ROBLES A,FLETCHER H M.Oxidative stress resistance in porphyromonas gingivalis［J］.Future Microbiol,2012,7(4):497-512.
［54］　TSAI C C,CHENG C Y,LIU C Y,KAO S C,KAU H C,WM H,et al.Oxidative stress in patients with Graves’ ophthalmopathy:relationship between oxidative DNA damage and clinical evolution［J］.Eye (Lond),2009,23(8):1725-1730.
［55］　TSAI C C,WU S B,CHENG C Y,KAO S C,KAU H C,CHIOU S H,et al.Increased oxidative DNA damage,lipid peroxidation,and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ophthalmopathy:evidence that oxidative stress has a role in this disorder［J］.Eye (Lond),2010,24(9):1520-1525.
［56］　CHOI W,LI Y,JI Y S,YOON K C.Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score［J］.BMC Ophthalmol,2018,18(1):303.
［57］　MA Y,ZHANG L,RONG S,QU H,ZHANG Y,CHANG D,et al.Relation between gastric cancer and protein oxidation,DNA damage,and lipid peroxidation［J］.Oxid Med Cell Longev,2013,2013:543760.
［58］　MATLACH J,FREIBERG F J,LEIPPI S,GREHN F,KLINK T.Comparison of phacotrabeculectomy versus phacocanaloplasty in the treatment of patients with concomitant cataract and glaucoma［J］.BMC Ophthalmol,2013,13:1.
［59］　KADRMAS E F,BARTLEY G B.Superior limbic keratoconjunctivitis［J］.Ophthalmology,1995,102(10):1472-1475.
［60］　CHNG C L,SEAH L L,YANG M,SHEN S Y,KOH S K,GAO Y,et al.Tear proteins Calcium binding protein a4 (S100A4) and prolactin induced protein (PIP) are potential biomarkers for thyroid eye disease［J］.Sci Rep,2018,8(1):16936.
［61］　IHEDIOHA O C,SHIU R P,UZONNA J E,MYAL Y.Prolactin-inducible protein:from breast cancer biomarker to immune modulator-novel insights from knockout mice［J］.DNA Cell Biol,2016,35(10):537-541.
［62］　KLINGEBORN M,WM D,BOWES R C,STAMER W D.Roles of exosomes in the normal and diseased eye［J］.Prog Retin Eye Res,2017,59:158-177.
［63］　AQRAWI L A,GALTUNG H K,GUERREIRO E M,OVSTEBO R,THIEDE B,UTHEIM T P,et al.Proteomic and histopathological characterisation of sicca subjects and primary Sjgren’s syndrome patients reveals promising tear,saliva and extracellular vesicle disease biomarkers［J］.Arthritis Res Ther,2019,21(1):181.
［64］　ROSSI C,CICALINI I,CUFARO M C,AGNIFILI L,MASTROPASQUA L,LANUTI P,et al.Multi-omics approach for studying tears in treatment-Nave glaucoma patients［J］.Int J Mol Sci,2019,20(16):4029.
［65］　PIERAGOSTINO D,LANUTI P,CICALINI I,CUFARO M C,CICCOCIOPPO F,RONCI M,et al.Proteomics characterization of extracellular vesicles sorted by flow cytometry reveals a disease-specific molecular cross-talk from cerebrospinal fluid and tears in multiple sclerosis［J］.J Proteomics,2019,204:103403.
［66］　HAN J S,KIM S E,JIN J Q,PARK N R,JY L,KIM H L,et al.Tear-derived exosome proteins are increased in patients with thyroid eye disease［J］.Int J Mol Sci,2021,22(3):1115.
［67］　AASS C,NORHEIM I,ERIKSEN E F,BORNICK E C,THORSBY P M,PEPAJ M.Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy［J］.PLoS One,2017,12(4):e0175274.
［68］　SHI T T,XIN Z,HUA L,ZHAO R X,YANG Y L,WANG H,et al.Alterations in the intestinal microbiota of patients with severe and active Graves’ orbitopathy:a cross-sectional study［J］.J Endocrinol Invest,2019,42(8):967-978.
［69］　ZHAO F,FENG J,LI J,ZHAO L,LIU Y,CHEN H,et al.Alterations of the gut microbiota in hashimoto’s thyroiditis patients［J］.Thyroid,2018,28(2):175-186.
［70］　KIM C Y,LEE H J,CHAE M K,BYUN J W,LEE E J,YOON J S.Therapeutic effect of resveratrol on oxidative stress in Graves’ orbitopathy orbital fibroblasts［J］.Invest Ophthalmol Vis Sci,2015,56(11):6352-6361.
［71］　SHI T T,XIN Z,HUA L,WANG H,ZHAO R X,YANG Y L,et al.Comparative assessment of gut microbial composition and function in patients with Graves’ disease and Graves’ orbitopathy［J］.J Endocrinol Invest,2021,44(2):297-310.
［72］　LI L,BOUNDS K R,CHATTERJEE P,GUPTA S.MicroRNA-130a,a potential antifibrotic target in cardiac fibrosis［J］.J Am Heart Assoc,2017,6(11):e006763.
［73］　JANG S Y,CHAE M K,LEE J H,LEE E J,YOON J S.Role of miR-146a in the regulation of inflammation in an in vitro model of Graves’orbitopathy［J］.Invest Ophthalmol Vis Sci,2016,57(10):4027-4034.
［74］　HAMMOND C L,ROZTOCIL E,GONZALEZ M,FELDON S E,WOELLER C F.MicroRNA-130a is elevated in thyroid eye disease and increases lipid accumulation in fibroblasts through the suppression of AMPK［J］.Invest Ophthalmol Vis Sci,2021,62(1):29.
［75］　WU Y,GUAN S,GE Y,YANG Y,CAO Y,ZHOU J.Cigarette smoke promotes chronic obstructive pulmonary disease (COPD) through the miR-130a/Wnt1 axis［J］.Toxicol In Vitro,2020,65:104770.
［76］　GILLESPIE E F,SMITH T J,DOUGLAS R S.Thyroid eye disease:towards an evidence base for treatment in the 21st century［J］.Curr Neurol Neurosci Rep,2012,12(3):318-324.

相似文献/References:

[1]杨忠昆 朱勤 胡竹林.改良三壁眶减压术治疗重症甲状腺相关性眼病的疗效观察[J].眼科新进展,2012,32(9):000.
[2]陆燕,黄媛媛,蔡季平,等. SB431542和TGF-β1对甲状腺相关性眼病患者眼眶成纤维细胞α-SMA及CTGF基因表达的影响[J].眼科新进展,2015,35(3):210.[doi:10.13389/j.cnki.rao.2015.0057]
　LU Yan,HUANG Yuan-Yuan,CAl Ji-Ping,et al. Effects of SB431542 and TGF-B1 0n a-SMA and CTGF gene expression in orbital fibroblast of patients with thyroid-associated ophthalmolopathy[J].Recent Advances in Ophthalmology,2015,35(7):210.[doi:10.13389/j.cnki.rao.2015.0057]
[3]徐婷婷,邵毅,周琼.泪液标志物在系统性疾病中的研究进展[J].眼科新进展,2017,37(8):780.[doi:10.13389/j.cnki.rao.2017.0198]
　XU Ting-Ting,SHAO Yi,ZHOU Qiong.Recent progression on tear fluid markers in systemic disease[J].Recent Advances in Ophthalmology,2017,37(7):780.[doi:10.13389/j.cnki.rao.2017.0198]
[4]李筱荣,石怡.黄斑中心凹无血管区在眼部疾病中的临床意义[J].眼科新进展,2020,40(5):401.[doi:10.13389/j.cnki.rao.2020.0093]
　LI Xiaorong,SHI Yi.Clinical significance of foveal avascular zone in ocular diseases[J].Recent Advances in Ophthalmology,2020,40(7):401.[doi:10.13389/j.cnki.rao.2020.0093]
[5]董敬红,薛嘉睿,张荣荣,等.病理性近视眼影像学生物标志物的研究现状[J].眼科新进展,2022,42(5):413.[doi:10.13389/j.cnki.rao.2022.0084]
　DONG Jinghong,XUE Jiarui,ZHANG Rongrong,et al.Update of imaging biomarkers of pathological myopia[J].Recent Advances in Ophthalmology,2022,42(7):413.[doi:10.13389/j.cnki.rao.2022.0084]
[6]何志伟,胡欣,陈国芳,等.抗氧化剂：治疗甲状腺相关性眼病的新选择[J].眼科新进展,2022,42(5):417.[doi:10.13389/j.cnki.rao.2022.0085]
　HE Zhiwei,HU Xin,CHEN Guofang,et al.Antioxidant: a new therapy for thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(7):417.[doi:10.13389/j.cnki.rao.2022.0085]
[7]王玲,樊芳,贾志旸.原发性青光眼生物标志物的研究进展[J].眼科新进展,2022,42(6):495.[doi:10.13389/j.cnki.rao.2022.0101]
　WANG Ling,FAN Fang,JIA Zhiyang.Advances in the study of biomarkers of primary glaucoma[J].Recent Advances in Ophthalmology,2022,42(7):495.[doi:10.13389/j.cnki.rao.2022.0101]

备注/Memo

备注/Memo:
吉林省教育厅科学研究项目（编号：JJKH20201089KJ）
更新日期/Last Update: 2022-07-05